Stock & Company Details
Exelixis Inc $EXEL
Price:
N/A
N/A
248M
$15B
52 Week High:
N/A
10 Day Average Volume:
N/A
18.54
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
EXEL technical indicators
Latest Exelixis Inc (EXEL) indicator readings as of 2026-10-09.
EXEL's 14-day RSI is 62.2, in neutral territory. At $59.86 it is trading 21.0% above its 200-day moving average of $49.47, and above its 50-day average of $56.14. Price sits above the upper Bollinger Band ($56.34 to $59.79). ADX reads 12.9, indicating a range-bound market rather than a trend.
EXEL backtested strategy results
How 4 rule-based strategies performed on Exelixis Inc (EXEL) over recent history, last backtested 2026-09-02. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +142.0% | 70% | 10 | -23.5% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -22.0% | 38% | 29 | -46.9% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -18.2% | 39% | 33 | -39.9% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | -14.8% | 62% | 21 | -40.6% |
Overview
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Finance Bot
Ask your questions
Start by typing a question below.
